Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients
Michel Obéid, Madeleine Suffiotti, Céline Pellaton, et al.
JAMA Oncology (2022) Vol. 8, Iss. 5, pp. e220446-e220446
Open Access | Times Cited: 62

Showing 1-25 of 62 citing articles:

SARS-CoV-2 in immunocompromised individuals
Susan DeWolf, Justin C. Laracy, Miguel‐Angel Perales, et al.
Immunity (2022) Vol. 55, Iss. 10, pp. 1779-1798
Open Access | Times Cited: 88
Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study
María‐Eugenia Zaballa, Javier Perez‐Saez, Carlos de Mestral, et al.
The Lancet Regional Health - Europe (2022) Vol. 24, pp. 100547-100547
Open Access | Times Cited: 41
Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys
Craig Fenwick, Priscilla Turelli, Dongchun Ni, et al.
Nature Microbiology (2022) Vol. 7, Iss. 9, pp. 1376-1389
Open Access | Times Cited: 39
Commercially Available Flavonols Are Better SARS-CoV-2 Inhibitors than Isoflavone and Flavones
Otávio Augusto Chaves, Natália Fintelman-Rodrigues, Xuanting Wang, et al.
Viruses (2022) Vol. 14, Iss. 7, pp. 1458-1458
Open Access | Times Cited: 38
Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron
Maximilian J. Mair, Manfred Mitterer, Pia Gattinger, et al.
Cancer Cell (2022) Vol. 40, Iss. 5, pp. 444-446
Open Access | Times Cited: 35
Incidence of Chronic Spontaneous Urticaria Following Receipt of the COVID-19 Vaccine Booster in Switzerland
Olivier Duperrex, Francesco Tommasini, Yannick D. Müller
JAMA Network Open (2023) Vol. 6, Iss. 2, pp. e2254298-e2254298
Open Access | Times Cited: 17
Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications
Yingying Shi, Miaoyuan Shi, Yì Wáng, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 5
Heterologous versus homologous boosting elicits qualitatively distinct, BA.5–cross-reactive T cells in transplant recipients
Elizabeth A. Thompson, Wabathi Ngecu, Laila Stoddart, et al.
JCI Insight (2023) Vol. 8, Iss. 10
Open Access | Times Cited: 10
Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma
Ashley Del Dosso, Elizabeth Tadevosyan, James R. Berenson
Oncotarget (2024) Vol. 15, Iss. 1, pp. 65-75
Open Access | Times Cited: 3
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis
Noppacharn Uaprasert, Palada Pitakkitnukun, Nuanrat Tangcheewinsirikul, et al.
Blood Cancer Journal (2022) Vol. 12, Iss. 12
Open Access | Times Cited: 17
SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study
Woo-Joong Kim, Seong‐Ho Choi, Ji Young Park, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 11, pp. 1585-1593
Open Access | Times Cited: 16
Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom’s Macroglobulinemia after BNT162b2 Booster Vaccination
Margherita Rosati, Evangelos Terpos, Jenifer Bear, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5816-5816
Open Access | Times Cited: 16
Chronic urticaria after Moderna COVID-19 vaccine boosters: A case series
Chenin Ryan, Kevin Li, Raven Bennett, et al.
JAAD Case Reports (2024) Vol. 45, pp. 27-30
Open Access | Times Cited: 2
Kinetics of the Neutralizing and Spike SARS-CoV-2 Antibodies following the Sinovac Inactivated Virus Vaccine Compared to the Pfizer mRNA Vaccine in Singapore
Chin Shern Lau, May Lin Helen Oh, Soon Kieng Phua, et al.
Antibodies (2022) Vol. 11, Iss. 2, pp. 38-38
Open Access | Times Cited: 13
Safety, tolerability, and pharmacokinetics of half-life extended SARS-CoV-2–neutralizing monoclonal antibodies AZD7442 (tixagevimab/cilgavimab) in healthy Japanese adults
Hiroshi Okada, Kensuke Ishikawa, Y. Itoh, et al.
Journal of Infection and Chemotherapy (2023) Vol. 29, Iss. 11, pp. 1061-1067
Open Access | Times Cited: 7
A novel plant‐made monoclonal antibody enhances the synergetic potency of an antibody cocktail against the SARS‐CoV‐2 Omicron variant
Collin Jugler, Haiyan Sun, Katherine Nguyen, et al.
Plant Biotechnology Journal (2022) Vol. 21, Iss. 3, pp. 549-559
Open Access | Times Cited: 11
CXCL12 and CXCL13 Cytokine Serum Levels Are Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses
Alessandra Noto, Victor Joo, Antonio Mancarella, et al.
Viruses (2022) Vol. 14, Iss. 12, pp. 2665-2665
Open Access | Times Cited: 11
Assessing Vulnerability to COVID-19 in High-Risk Populations: The Role of SARS-CoV-2 Spike-Targeted Serology
Harvey W. Kaufman, William A. Meyer, Nigel J. Clarke, et al.
Population Health Management (2023) Vol. 26, Iss. 1, pp. 29-36
Open Access | Times Cited: 6
Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland
María-Eugenia Zaballa, Javier Perez‐Saez, Carlos de Mestral, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 10
IgG anti-RBD levels during 8-month follow-up post-vaccination with BNT162b2 and mRNA-1273 vaccines in healthcare workers: A one-center study
Sergio Gil-Manso, Roberto Alonso, Pilar Catalán, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 10
Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patients
Oliver Overheu, Simon Lendowski, Daniel R. Quast, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 12, pp. 10633-10644
Open Access | Times Cited: 5
Updated COVID‐19 clearance time among patients with cancer in the Delta and Omicron waves
Zachary M. Avigan, Rodrigo Paredes, Leora Boussi, et al.
Cancer Medicine (2023) Vol. 12, Iss. 16, pp. 16869-16875
Open Access | Times Cited: 5
Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys
Craig Fenwick, Priscilla Turelli, Yoan Duhoo, et al.
Journal of Infection (2023) Vol. 87, Iss. 6, pp. 524-537
Open Access | Times Cited: 5
The impact of COVID-19 on cancer patients
Demi Wekking, Thilini H. Senevirathne, Josie Pearce, et al.
Cytokine & Growth Factor Reviews (2023) Vol. 75, pp. 110-118
Closed Access | Times Cited: 5
The SARS-CoV-2 Pandemic and Cancer Trials Ireland: Impact, Resolution and Legacy
Séamus O’Reilly, Verena Murphy, Eibhlin Mulroe, et al.
Cancers (2022) Vol. 14, Iss. 9, pp. 2247-2247
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top